Results 211 to 218 of about 7,072 (218)

Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis

Lancet, The
Alasdair D Henderson, Carolyn S P Lam, Sanjiv J Shah   +2 more
exaly  

Why Have We Not Been Able to Demonstrate Reduced Mortality in Patients With HFmrEF/HFpEF?

Journal of the American College of Cardiology
Alasdair D Henderson, Kieran F Docherty, Toru Kondo   +2 more
exaly  

Both HFpEF and HFmrEF should be included in calculating CHA2DS2-VASc score: A Taiwanese longitudinal cohort

Heart Rhythm
Shelly Chien-Chien Cheng, Jien Jiun Chen, Fu-Chun Chiu   +2 more
exaly  

Impact of non-cardiac comorbidities on diastolic properties in HFREF and HFmrEF patients

2022
Giorgia Serino, Annalisa Caputo, Domenico Filomena, Giovanna Manzi, Matteo Neccia, Michela Boromei, Giovanni Rubino, Silvia Papa, Carmine Dario Vizza, Roberto Badagliacca   +9 more
openaire   +1 more source

Non-cardiac comorbidities in HFrEF, HFmrEF and HFpEF - findings from BIOSTAT-CHF

European Journal of Heart Failure, 2017
Streng, K.W., Nauta, J.F., Hillege, J.L., Anker, S.D., Cleland, J.G., Lang, C.C., Metra, M., Ng, L., van Veldhuisen, D.J., Zwinderman, A., Zannad, F., Damman, K., Van Der Meer, P., Voors, A.A.   +13 more
openaire  

AL-CARDIAC AMYLOIDOSIS PRESENTING AS HFMREF: A UNUSUAL PRESENTATION OF AN UNCOMMON DISEASE

Journal of the American College of Cardiology
Ishan Garg, Kenneth Zabel, Abu Baker Sheikh   +2 more
openaire   +1 more source

SGLT2 INHIBITORS IN HFPEF AND HFMREF: A COMPREHENSIVE PRISMA SYSTEMATIC REVIEW

openaire   +1 more source

HFmrEF und HFpEF: Nutzen von Dapagliflozin bleibt auch bei verminderter eGFR erhalten

CardioVasc
openaire   +1 more source